Schwebs Timo, Kieninger Ann-Katrin, Podpera Tisakova Lenka, Oberbauer Vera, Berdaguer Rocío, Mtshali Andile, Mzobe Gugulethu, Rompalo Anne, Mindel Adrian, Letsoalo Marothi, Garrett Nigel, Ngcapu Sinaye, Corsini Lorenzo
BioNTech R&D (Austria) GmbH, Helmut-Qualtinger-Gasse 2, 1030 Vienna, Austria.
Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban 4013, South Africa.
Antibiotics (Basel). 2024 Dec 14;13(12):1217. doi: 10.3390/antibiotics13121217.
: The high recurrence rate of bacterial vaginosis (BV) after antibiotic treatment is at least partially attributed to resistant bacteria. The CAPRISA 083 (CAP083) study investigated the influence of metronidazole (MTZ) treatment on the vaginal microbiome in 56 South African women diagnosed with BV. To explore the etiology of recurrent BV in this cohort, we retrospectively analyzed vaginal swabs collected in CAP083 before and after MTZ treatment. : We isolated over 1200 bacterial strains, including , and , and determined the minimum inhibitory concentration (MIC) of MTZ and the resistance status according to CLSI and EUCAST guidelines. : At baseline, 64% (CLSI) of isolates were resistant to MTZ, rising to 80% after MTZ treatment by the 12-week visit. species consistently exhibited resistance of 100%, while maintained resistance rates of 78-91% across visits. strains varied, showing two susceptible isolates at baseline and one resistant isolate at the 6-week visit. Susceptible and resistant isolates were often isolated from the same swab, and 70% (CLSI) of participants had at least one resistant strain already at baseline. Sensitive isolates were not a predictor of an MTZ-mediated reduction in abundance. : Our data indicate that the 23% cure rate in CAP083 was associated with a combination of a high share of MTZ-resistant bacteria at baseline, a potentially insufficient MTZ dose regimen, and a constantly high average abundance of . Future research should explore novel therapeutic strategies to enhance treatment efficacy and combat antibiotic resistance.
细菌性阴道病(BV)在抗生素治疗后的高复发率至少部分归因于耐药菌。CAPRISA 083(CAP083)研究调查了甲硝唑(MTZ)治疗对56名被诊断为BV的南非女性阴道微生物群的影响。为了探究该队列中复发性BV的病因,我们回顾性分析了CAP083研究中MTZ治疗前后收集的阴道拭子。我们分离出1200多种细菌菌株,包括[具体菌株名称未给出],并根据CLSI和EUCAST指南确定了MTZ的最低抑菌浓度(MIC)和耐药状态。基线时,[具体菌株名称未给出]分离株中有64%(CLSI标准)对MTZ耐药,在12周随访时MTZ治疗后升至80%。[具体菌株名称未给出]物种始终表现出100%的耐药性,而[具体菌株名称未给出]在各次随访中耐药率维持在78 - 91%。[具体菌株名称未给出]菌株情况各异,基线时有两个敏感分离株,6周随访时有一个耐药分离株。敏感和耐药的[具体菌株名称未给出]分离株常从同一拭子中分离出来,70%(CLSI标准)的参与者在基线时就至少有一株耐药的[具体菌株名称未给出]菌株。敏感的[具体菌株名称未给出]分离株并非MTZ介导的[具体菌株名称未给出]丰度降低的预测指标。我们的数据表明,CAP083研究中23%的治愈率与基线时MTZ耐药菌比例高、MTZ剂量方案可能不足以及[具体菌株名称未给出]的平均丰度持续居高有关。未来的研究应探索新的治疗策略以提高治疗效果并对抗抗生素耐药性。